Clinical Trials
24 trialsBevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
CORIN
Sun Yat-sen University
IcomBine
Sun Yat-sen University
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
Peking University Cancer Hospital & Institute
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Liaoning Cancer Hospital & Institute
NeoIpower
Peking University Cancer Hospital & Institute
Icotinib
Beijing Tiantan Hospital
ALTER-L004
Tianjin Medical University Cancer Institute and Hospital
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Sun Yat-sen University
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in â…¢b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Sun Yat-sen University
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
Sichuan Cancer Hospital and Research Institute
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Anhui Medical University
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
China Medical University, China
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Beijing Haidian Hospital
RT Plus EGFR-TKI for Wild-type NSCLC
Hangzhou Cancer Hospital
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
First People's Hospital of Hangzhou
Chemotherapy of NSCLC With or Without Icotinib
Nanfang Hospital, Southern Medical University
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Zhejiang University
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer
Zhejiang University
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Shandong Cancer Hospital and Institute
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Zhejiang Cancer Hospital
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Zhejiang Cancer Hospital